The "gold standard" for the treatment of primary apnea in premature infants

The basis of Ozelair® action in apnea in premature infants is the stimulation of the central nervous system by several mechanisms:
- stimulation of respiratory centers;
- increase in the minute volume of lung ventilation;
- lowering the threshold of carbon dioxide in the blood;
- increase the response to the content of carbon dioxide in the blood;
- increase in skeletal muscle tone;
- reduction of diaphragmatic fatigue;
- increased metabolic rate;
- increased oxygen consumption.


 

Pharmaceutical form: solution for infusion and oral use
Strength: 20 mg/ml
Primary packaging: ampoules 1 ml
Indication: treatment of primary apnea in premature infants.